INS and Cushing syndrome: During metabolic dysfunction, insulin secreting pancreatic beta cells can no longer compensate for hyperglycaemia, and long-term exposure to high levels of exogenous or endogenous GC during therapeutic administration of Cushing’s syndrome, respectively, reduce insulin secretion and induce a diabetes-like phenotype [64].